Crucell corporate brochure (PDF)

Crucell’s commitment to the world – Taking responsibility
Recruitment and operational improvements in our R&D groups were a high
priority during 2010. Dr Jerald Sadoff, a veteran of vaccine development
and former director of the Aeras Global TB Vaccine Foundation, joined
Crucell as Chief Medical Officer & Head of Development in March 2010.
He brings with him a wealth of experience and enthusiasm to take
Crucell’s pipeline products to market in the shortest possible time.
While working on the discovery and development of new vaccines
and antibody products, Crucell also invests in programs that will
increase the value and reach of existing products. A prime example
of this sort of lifecycle development is our project to make Quinvaxem®
available in Uniject, an ingenious vaccine delivery device designed
to meet the immunization needs of developing countries (see box).
Other examples are our efforts to launch Epaxal® hepatitis A vaccine
on the US market and our R&D program to add a sixth vaccine to
the Quinvaxem® combination.
Success and setback
A total of 68.9 million doses of Quinvaxem® vaccine, Crucell’s lead
product, were delivered to developing countries in 2010, compared to
64.3 million in 2009. Quinvaxem® is a fully liquid pentavalent (five-inone)
vaccine that protects against five major childhood diseases. It
was developed specifically to meet the needs of countries with limited
resources and is making a major contribution towards achieving the
United Nations Millennium Development Goal of reducing the mortality
rate among children under five by two-thirds between 1990 and 2015.
In 2010, Vietnam joined the growing number of recipient countries
after the Vietnamese health authorities registered Quinvaxem® for use
in the national immunization program. The first shipment was sent to
Vietnam in April 2010—a month in which we shipped a record number
of Quinvaxem® doses.
Fill and finish operations started at our new Korean production facility mid-2010.
Quinvaxem® vaccines sold
(Doses in million units)
6.3
21.9
39.6
64.3 68.9
2006 2007 2008 2009 2010
45